Sensus Healthcare Inc (SRTS) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

GuruFocus.com11-15

Revenue: $8.8 million for Q3 2024, up 127% from $3.9 million in Q3 2023. Gross Profit: $5.2 million or 59.3% of revenues for Q3 2024, compared to $2 million or 51% in Q3 2023. Net Income: $1.2 million...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483391310?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xhGdkCAE6.HcCtky2dMeuw--~B/aD0xNDM7dz0zNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a59893c491204b98cc8ab1faa0b08582","is_english":true,"pubTime":"2024-11-15 15:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483391310","market":"us","top_or_hot":-1,"title":"Sensus Healthcare Inc (SRTS) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $8.8 million for Q3 2024, up 127% from $3.9 million in Q3 2023.\nGross Profit: $5.2 million or 59.3% of revenues for Q3 2024, compared to $2 million or 51% in Q3 2023.\nNet Income: $1.2 million...</p>\n\n<a href=\"https://finance.yahoo.com/news/sensus-healthcare-inc-srts-q3-071559297.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sensus Healthcare Inc (SRTS) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSensus Healthcare Inc (SRTS) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 15:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sensus-healthcare-inc-srts-q3-071559297.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $8.8 million for Q3 2024, up 127% from $3.9 million in Q3 2023.\nGross Profit: $5.2 million or 59.3% of revenues for Q3 2024, compared to $2 million or 51% in Q3 2023.\nNet Income: $1.2 million...</p>\n\n<a href=\"https://finance.yahoo.com/news/sensus-healthcare-inc-srts-q3-071559297.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRTS","symbol_name":"Sensus Healthcare, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/sensus-healthcare-inc-srts-q3-071559297.html","article_id":"2483391310","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xhGdkCAE6.HcCtky2dMeuw--~B/aD0xNDM7dz0zNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/a59893c491204b98cc8ab1faa0b08582"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483391310","pubTimestamp":1731654959,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $8.8 million for Q3 2024, up 127% from $3.9 million in Q3 2023.Gross Profit: $5.2 million or 59.3% of revenues for Q3 2024, compared to $2 million or 51% in Q3 2023.Net Income: $1.2 million or $0.07 per diluted share for Q3 2024, compared to a net loss of $1.5 million or a loss of $0.09 per share in Q3 2023.Adjusted EBITDA: $1.6 million for Q3 2024, compared to negative $1.7 million in Q3 2023.Units Shipped: 27 SRT systems in Q3 2024, compared to 11 in Q3 2023.Cash and Cash Equivalents: $22.6 million as of September 30, 2024.Accounts Receivables: $17 million as of September 30, 2024, with approximately $8 million collected.Total Inventories: $12 million as of September 30, 2024.GuruFocus has detected 5 Warning Signs with SRTS.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Sensus Healthcare Inc  continues to expand its global presence, shipping systems to international markets such as Israel and engaging in the veterinary mar","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SRTS":"Sensus Healthcare, Inc."},"translate_title":"Sensus Healthcare Inc(SRTS)2024年第三季度收益看涨期权亮点：收入激增和战略……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRTS":1},"content_text":"Revenue: $8.8 million for Q3 2024, up 127% from $3.9 million in Q3 2023.\nGross Profit: $5.2 million or 59.3% of revenues for Q3 2024, compared to $2 million or 51% in Q3 2023.\nNet Income: $1.2 million or $0.07 per diluted share for Q3 2024, compared to a net loss of $1.5 million or a loss of $0.09 per share in Q3 2023.\nAdjusted EBITDA: $1.6 million for Q3 2024, compared to negative $1.7 million in Q3 2023.\nUnits Shipped: 27 SRT systems in Q3 2024, compared to 11 in Q3 2023.\nCash and Cash Equivalents: $22.6 million as of September 30, 2024.\nAccounts Receivables: $17 million as of September 30, 2024, with approximately $8 million collected.\nTotal Inventories: $12 million as of September 30, 2024.\n\n\nWarning! GuruFocus has detected 5 Warning Signs with SRTS.\n\nRelease Date: November 14, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nRevenues more than doubled year-over-year for the second consecutive quarter, reaching $8.8 million in Q3 2024.\nSensus Healthcare Inc (NASDAQ:SRTS) maintained profitability despite the summer seasonality, with a net income of $1.2 million compared to a net loss in the previous year.\nThe company signed a significant Fair Deal agreement with Platinum Dermatology Partners, covering 130 clinical sites in the US, which is expected to contribute to future growth.\nGross profit margin improved to 59.3% in Q3 2024 from 51% in the same quarter last year.\nSensus Healthcare Inc (NASDAQ:SRTS) continues to expand its global presence, shipping systems to international markets such as Israel and engaging in the veterinary market.\n\n Negative Points \n\nThe accidental disclosure of financial results during live trading hours was a procedural setback.\nThe hospital market, while promising, has a longer sales cycle, potentially delaying revenue realization.\nGeneral and administrative expenses increased slightly due to higher compensation and bad debt expenses.\nThe Fair Deal agreement, while promising, does not immediately impact sales numbers as it is based on recurring revenue.\nThe company's largest customer represents about 50% of placements, indicating a potential risk of over-reliance on a single client.\n\n Q & A Highlights \nQ: With the Fair Deal agreement with Platinum Dermatology Partners, does that imply you'll be signing contracts for the remaining 130 clinics, and how might that cascade into 2025? A: The contract covers all 130 sites, so no additional contracts are needed. We will conduct surveys at various sites to install systems as quickly as possible, which will likely extend into next year with ongoing requests for additional products. \nQ: What percentage of placements are related to your largest customer? A: Our largest customer represents about 50% of placements.\nQ: Regarding the Fair Deal agreement with Platinum Dermatology, have they indicated how many systems they intend to procure under the agreement in 2025? A: Platinum Dermatology requested that the agreement be open for all 130 sites, allowing them the option to install a unit at each site. This will be an ongoing process as they continue to expand.\nQ: Are you in negotiations with other large dermatology practices similar in size to Platinum Dermatology? A: Yes, there are about 12 to 15 companies that are private equity-sponsored, and several are reviewing our contracts.\nQ: How are you pursuing demand in the international market, and is the Fair Deal agreement available there? A: The Fair Deal agreement is not currently offered internationally. We are expanding through distributors, with recent interest from Southeast Asia, including Vietnam, Laos, and Cambodia.\nQ: What would you attribute to the outperformance in the third quarter, traditionally a quiet period? A: The third quarter did not recognize any contribution from the Platinum deal. The outperformance is due to increased revenues from existing FDA agreements and installations, with significant revenue expected in the second half of 2025.\nQ: Will your production capacity be enough to serve large orders like the one from Platinum Dermatology? A: Yes, we have the capacity to handle the volume. Installations are systematic, involving training and construction, and we have enough inventory to cover 2025.\nQ: Could you provide any comment on the target number of systems shipped or Fair Deal agreements expected next year? A: We do not provide specific guidance but aim to maximize shipments and agreements. Interest is expected to increase as we work with companies like Platinum.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483391310"}